MARKET

ZGNX

ZGNX

Zogenix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.68
+0.42
+2.07%
Opening 15:36 03/05 EST
OPEN
20.35
PREV CLOSE
20.26
HIGH
20.70
LOW
19.38
VOLUME
467.28K
TURNOVER
--
52 WEEK HIGH
32.42
52 WEEK LOW
16.65
MARKET CAP
1.15B
P/E (TTM)
-5.3853
1D
5D
1M
3M
1Y
5Y
Needleless Syringe Market Size, Share, Growth 2021 Global Industry Analysis by Trends, Demand, Technology Progress, Company Overview Forecast to 2026
Mar 03, 2021 (The Expresswire) -- Global“Needleless Syringe Market” 2021 Industry Research Report is a back to front and master assessment on the stream...
The Express Wire · 2d ago
Needle-free Drug Delivery Devices Market Growth, Size 2021 Global Industry Analysis, Share, Trends, Market Demand, Growth, Top Manufacturers, Opportunities Forecast to 2026
Mar 03, 2021 (The Expresswire) -- “Final Report will add the analysis of the impact of COVID-19 on this industry." “ Needle-free Drug Delivery Devices...
The Express Wire · 2d ago
Zogenix to Participate in the Raymond James Institutional Investors Conference
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will present a corporate overview and pa...
GlobeNewswire · 3d ago
10-K: ZOGENIX, INC.
(EDGAR Online via COMTEX) -- ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION Please read the following...
Edgar Online - (EDG = 10Q, 10K) · 3d ago
Competitive Scenario of Needle-free Drug Delivery Devices Market Growth, Size, Demand, Forecast with Depth Assessment by Top Key Players 2026
Mar 01, 2021 (The Expresswire) -- Global “Needle-free Drug Delivery Devices Market” (2021-2026) to its vast repository and growth prospects of the market...
The Express Wire · 4d ago
Needham Sticks to Their Buy Rating for Zogenix (ZGNX)
Needham analyst Serge Belanger maintained a Buy rating on Zogenix (ZGNX) today and set a price target of $48.00. The company's shares closed last Friday
SmarterAnalyst · 02/26 19:05
Zogenix (ZGNX) Receives a Hold from Raymond James
In a report released yesterday, Danielle Brill from Raymond James maintained a Hold rating on Zogenix (ZGNX). The company's shares closed last Thursday at
SmarterAnalyst · 02/26 13:24
DJ Zogenix, Inc. CEO Stephen Farr on Q4 2020 Results -- Earnings Call Transcript >ZGNX
Dow Jones · 02/26 04:44
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZGNX. Analyze the recent business situations of Zogenix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZGNX stock price target is 48.70 with a high estimate of 65.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 291
Institutional Holdings: 70.21M
% Owned: 125.97%
Shares Outstanding: 55.74M
TypeInstitutionsShares
Increased
52
11.30M
New
57
-1.93M
Decreased
52
5.36M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.98%
Pharmaceuticals & Medical Research
+1.29%
Key Executives
Chairman/Independent Director
Cam Garner
President/Chief Executive Officer/Director
Stephen Farr
Chief Financial Officer/Executive Vice President/Treasurer
Michael Smith
Executive Vice President/General Counsel/Secretary
Shawnte Mitchell
Executive Vice President
Gail Farfel
Executive Vice President
Bradley Galer
Executive Vice President
Ashish Sagrolikar
Independent Director
Louis Bock
Independent Director
James Breitmeyer
Independent Director
Caroline Loewy
Independent Director
Erle Mast
Independent Director
Mary Stutts
Independent Director
Renee Tannenbaum
Independent Director
Denelle Waynick
Independent Director
Mark Wiggins
No Data
About ZGNX
Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

Webull offers kinds of Zogenix, Inc. stock information, including NASDAQ:ZGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZGNX stock methods without spending real money on the virtual paper trading platform.